Valued at a market cap of $546.47 billion, Eli Lilly (LLY) is among the largest healthcare companies globally. It is engaged in the discovery, development, manufacture, and sales of pharmaceutical products, ranging from diabetes and oncology to immunology and neuroscience.
One of the key drivers of Eli Lilly’s top-line growth recently is its type 2 diabetes treatment, Mounjaro, which was approved in May 2022. The drug is widely used off-label as a weight-loss aid, and competes against Novo Nordisk's (NVO) blockbuster offerings, Ozempic and Wegovy.
